Background: With breast implant–associated anaplastic large cell lymphoma (BIA-ALCL)
now accepted as a unique (iatrogenic) subtype of ALCL directly associated with textured …

Background Laboratory and clinical research on breast implant–associated anaplastic large
cell lymphoma (BIA-ALCL) is rapidly evolving. Changes in standard of care and insights into …

Abstract National Comprehensive Cancer Network (NCCN) guidelines represent the
consensus standard of care for diagnosis and management of the majority of known …

Background: Breast implant–associated anaplastic large cell lymphoma (ALCL) is a
distinctive type of T-cell lymphoma that arises around breast implants. Although rare, all …

Background The risk of BIA-ALCL for patients with textured breast implants has been
estimated between 1/2832 and 1/30,000 women. Existing studies estimating the numbers …

Breast implant-associated anaplastic large cell lymphoma is a newly recognized provisional
entity in the 2017 revision of the World Health Organization Classification of Tumors of …

The goal of this continuing medical education module is to present the assessment of a
patient with suspected breast implant–associated anaplastic large cell lymphoma, the …

Shared strategies and correct information are essential to guide physicians in the
management of such an uncommon disease as Breast Implant–Associated Anaplastic Large …

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-
cell, CD-30+/ALK lymphoma. Late (9 years) periprosthetic fluid (seroma) is the most …

Background: Tracking world cases of breast implant–associated anaplastic large cell
lymphoma (ALCL) is currently limited to patient registries at a few academic centers …